# CheckMate 9UT (NCT03519256)

> A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus BCG; nivolumab plus linrodostat (BMS-986205)
- Indication: BCG-unresponsive high-risk non-muscle invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03519256
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Bristol-Myers Squibb
- Conditions: Urinary Bladder Neoplasms
- Interventions: Nivolumab; BCG; BMS-986205
- Enrollment: 142
- Primary outcome: Number of Participants With Adverse Events (AEs)
- Primary outcome: Number of Participants With Serious Adverse Events (SAEs)
- Primary outcome: Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment
- Primary outcome: Number of Participants Immune-Mediated Adverse Events (IMAEs)
- Primary outcome: Number of Participants Who Died
- Primary outcome: Number of Participants With Specific Liver Laboratory Abnormalities
- Primary outcome: Number of Participants With Specific Thyroid Laboratory Abnormalities
- Primary outcome: Number of Participants With Changes From Baseline Laboratory Values
- Primary outcome: Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status
- Primary outcome: Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status

## Indexed commentary on CheckMate 9UT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=checkmate-9ut-nct03519256